These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18312861)

  • 21. Isocyanide Multicomponent Reactions on Solid Phase: State of the Art and Future Application.
    Cankařová N; Krchňák V
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-throughput screening technologies for drug glucuronidation profiling.
    Trubetskoy O; Finel M; Trubetskoy V
    J Pharm Pharmacol; 2008 Aug; 60(8):1061-7. PubMed ID: 18644198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bringing primary cells to mainstream drug development and drug testing.
    Goldbard S
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):110-6. PubMed ID: 16445123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors.
    Zawahir Z; Dayam R; Deng J; Pereira C; Neamati N
    J Med Chem; 2009 Jan; 52(1):20-32. PubMed ID: 19072053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical robust fit of enzyme inhibition data.
    Kuzmic P; Hill C; Janc JW
    Methods Enzymol; 2004; 383():366-81. PubMed ID: 15063658
    [No Abstract]   [Full Text] [Related]  

  • 26. Picking pockets to fuel antimicrobial drug discovery.
    Hunter WN
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):980-4. PubMed ID: 17956259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial drug discovery.
    Fairlamb A; Cole S
    Future Microbiol; 2011 Jun; 6(6):601-2. PubMed ID: 21707305
    [No Abstract]   [Full Text] [Related]  

  • 28. Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening.
    Park H; Bahn YJ; Jung SK; Jeong DG; Lee SH; Seo I; Yoon TS; Kim SJ; Ryu SE
    J Med Chem; 2008 Sep; 51(18):5533-41. PubMed ID: 18714978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From purified GPCRs to drug discovery: the promise of protein-based methodologies.
    Alkhalfioui F; Magnin T; Wagner R
    Curr Opin Pharmacol; 2009 Oct; 9(5):629-35. PubMed ID: 19443270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of virtual screening as a tool for chemical genetic applications.
    Campagna-Slater V; Schapira M
    J Chem Inf Model; 2009 Sep; 49(9):2082-91. PubMed ID: 19702241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico systems biology approaches for the identification of antimicrobial targets.
    Sarker M; Talcott C; Galande AK
    Methods Mol Biol; 2013; 993():13-30. PubMed ID: 23568461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Norbornane compounds in pharmaceutical research.
    Buchbauer G; Pauzenberger I
    Pharmazie; 1999 Jan; 54(1):5-18. PubMed ID: 9987792
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibition and induction of human cytochrome P450 enzymes: current status.
    Pelkonen O; Turpeinen M; Hakkola J; Honkakoski P; Hukkanen J; Raunio H
    Arch Toxicol; 2008 Oct; 82(10):667-715. PubMed ID: 18618097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
    Miguet L; Zervosen A; Gerards T; Pasha FA; Luxen A; Distèche-Nguyen M; Thomas A
    J Med Chem; 2009 Oct; 52(19):5926-36. PubMed ID: 19746934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scoring ligand similarity in structure-based virtual screening.
    Zavodszky MI; Rohatgi A; Van Voorst JR; Yan H; Kuhn LA
    J Mol Recognit; 2009; 22(4):280-92. PubMed ID: 19235177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In silico fragment screening by replica generation (FSRG) method for fragment-based drug design.
    Fukunishi Y; Mashimo T; Orita M; Ohno K; Nakamura H
    J Chem Inf Model; 2009 Apr; 49(4):925-33. PubMed ID: 19354203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a high-throughput screening system for the compounds that inhibit collagen-protein interactions.
    Okano-Kosugi H; Matsushita O; Asada S; Herr AB; Kitagawa K; Koide T
    Anal Biochem; 2009 Nov; 394(1):125-31. PubMed ID: 19615329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targets looking for drugs: a multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery.
    Tintori C; Corradi V; Magnani M; Manetti F; Botta M
    J Chem Inf Model; 2008 Nov; 48(11):2166-79. PubMed ID: 18942779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening.
    Tanrikulu Y; Schneider G
    Nat Rev Drug Discov; 2008 Aug; 7(8):667-77. PubMed ID: 18636071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isocyanide-based multicomponent reactions towards cyclic constrained peptidomimetics.
    Koopmanschap G; Ruijter E; Orru RV
    Beilstein J Org Chem; 2014; 10():544-98. PubMed ID: 24605172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.